V451 vaccine
(Redirected from V451)
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target disease | COVID-19 |
| Clinical data | |
| Routes of administration | Intramuscular injection |
V451 was a vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology,[1] and the MF59 adjuvant.[2]
The development of the vaccine was cancelled on 11 December 2020 after false-positive tests for HIV antibodies in a number of participants in the Phase I trial of the vaccine.[3][4] As part of the vaccine's design, researchers added "small amounts of HIV protein" as a "ground-breaking molecular clamp technology"[5] which led to "a partial antibody response" to HIV and would have interfered with HIV screening tests.[6]
References[edit]
- ^ "UQ-CSL V451 Vaccine". www.precisionvaccinations.com. Retrieved 2020-12-11.
- ^ Meneguzzi J (13 November 2020). "Why a COVID-19 vaccine could further imperil deep-sea sharks". National Geographic.
- ^ "Covid: Australian vaccine abandoned over false HIV response". BBC News. 2020-12-11. Retrieved 2020-12-11.
- ^ Reuters Staff (2020-12-10). "BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials". Reuters. Retrieved 2020-12-11.
- ^ Smyth J (11 December 2020). "Australia abandons local Covid vaccine over HIV test concerns". Financial Times.
- ^ "Australia ends local COVID vaccine trials due to HIV false positives". Deutsche Welle. 11 December 2020.
External links[edit]
- Clinical trial number NCT04495933 for "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults" at ClinicalTrials.gov
 | This Australia-related article is a stub. You can help Wikipedia by expanding it. |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |